Targeting DARKFOXTM, A Novel Tumour-Specific Antigen Derived from FOXM1, With Bispecific T-cell Engagers

• Enara’s proprietary EDAPT® platform interrogates the dark genome to discover and validate novel, cancer-specific peptide-HLA and cell surface antigens with hallmarks of optimal cancer targets
• DARKFOXTM is a previously undescribed alternative open reading frame (alt-ORF) contained in the exonic sequence of FOXM1. DARKFOXTM alt-ORF encodes a short polypeptide, from which we identified several Class I HLA peptides on primary tumours by immunopeptidomics. We have designed bispecific T-cell engagers targeting DARKFOX using a rational, fit-for-purpose engineering strategy
• We demonstrate robust in vivo anti-tumour efficacy, showing strong tumour regression and highlighting that DARKFOXTM is an attractive cancer antigen for peptide-HLA targeted bispecific T-cell engagers

Speakers:

Colette Johnston

Vice President & Head of Product Platform Research

Enara Bio